Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
← catalyst calendarSponsored by Vera Therapeutics, Inc. (industry) · VERA — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
0actual
Sites
33
Countries
Puerto Rico, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-02 | actual | When the study began enrolling |
| Primary completion | 2026-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus Nephritis (LN)
Interventions
- Drug: Atacicept — also filed as VT-001
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFRenal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%
measured Week 52
Permalink · VERA's whole pipeline · Catalyst calendar · Every registered study · What changed